AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04104022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Within the general population, prolonged exposure therapy (PET) is a widely-used, empirically-supported and manualized therapy that is regarded as a first-line cognitive-behavioral treatment for posttraumatic stress disorder (PTSD). PET is designed to disrupt the cycle of anxiety and avoidance that characterizes PTSD via sustained imaginal and in-vivo exposure exercises that deliberately and systematically expose patients to painful memories and current, real-life trauma reminders that were previously avoided, yet not inherently harmful. Overall, PET has well-documented efficacy for reducing PTSD symptom severity in both civilian and veteran populations. PET is effective for reducing PTSD symptoms regardless of whether it is delivered remotely or face-to-face. Recent data also suggest that PET can improve PTSD symptoms without exacerbating substance use or craving among patients with substance use disorders when PET and substance use disorder treatment are delivered concurrently.
Study NCT04104022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attendance-based monetary incentives
Description: Participants will earn vouchers that have monetary value for attending scheduled PET appointments. Each consecutive attended session will increase the voucher amount so that each consecutively attended appointment is worth an incrementally higher dollar amount. To support completion of the full 12-week PET protocol, we will also incorporate additional strategically-placed bonuses into the reinforcement schedule with the goal of maximizing the percentage of subjects who complete the full 12-session protocol. First, to support consistent (vs. sporadic) attendance, participants will receive a bonus for every two consecutive sessions attended. Second, to support completion of the full PET protocol, participants will receive an additional bonus upon completion of Session 12.
Study NCT06162013 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside 3000mg/day
Study NCT06162013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. Identical in taste and appearance as the intervention.
Study NCT06096545 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary sentinal lymph node biopsy
Description: For SLNB evaluation, multiple sections of the excised lymph node were stained with hematoxylin and eosin (H\&E) at a thickness greater than 2 mm. Lymph nodes with metastasis greater than 2 mm were defined as positive SLNB. Macroscopic metastasis was considered positive in the evaluation for the axilla, while benign histological characteristics were considered negative. The presence of micrometastasis and isolated tumor cells was also noted. The size and diameter of the metastatic lymph node were considered in the evaluation.~SLNB technique using isosulfan blue dye was performed for axillary evaluation, and all patients had the clipped lymph node excised under ultrasound guidance with a guide wire placed preoperatively.
Study NCT05621668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study NCT05621668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: attIL2-T cells
Description: Given by IV (vein)
Study NCT05044325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3884464
Description: GSK3884464 will be administered
Study NCT05044325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match GSK3884464 will be administered.
Study NCT05256030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speed-based relearning training
Description: Spasticity, balance and gait exercises will be started at slow speeds, at muscle level, and in the following sessions, movement speed will be increased in relation to the patient's compliance, and global balance and gait exercises will be performed.
Study NCT05256030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Therapy
Description: Neurodevelopmental Therapy
Study NCT05731947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revumenib
Description: Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Study NCT05731947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.
Study NCT05330130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta injection 150 IU
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Study NCT05330130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta injection 300 IU
Description: Participants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time:~* one follicle on the morning of day 5, before the administration of the first GnRH-antagonist~* one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm~* two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation.~Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Study NCT05526963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication plan review
Description: Intervention group patients will receive a revised medication plan by external pharmacologist based on the the STOPP/START criteria. The revised medication plan will be provided to the family physician who then will provide it to the patient. The revision comes along with evidence based information for the physician to prevent possible uncertainties by the physicians.
Study NCT05526963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence support
Description: Intervention group patients will receive a study nurse administered adherence support measure based on telephone-based motivational interviewing. The measure includes information on possible consequences of inadherence and signs of adverse drug reactions that is comprehensible for lay persons.
Study NCT04804358 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exposition Test
Description: During this test (7 minutes) participants will be exposed to photos evoking positive or negative emotions (anger, disgust, sadness and fear) interspersed with emotionally neutral photos.~The test sequence is composed of 3 blocks as follows:~* 12 photos evoking positive emotions (2 min)~* Pause of 30 seconds (white screen)~* 12 photos presenting a neutral emotional valence (2 min)~* Pause of 30 seconds (white screen)~* 12 photos evoking negative emotions (2min)~In each block, photos will be selected and presented to the participant in a randomized and sequential manner. In total, 30 photos will be presented in 7 minutes to each participant (10 seconds per photo).~The participant must be at rest in front of the computer screen during these 7 minutes with optimal visibility. The photos will be presented sequentially using software (E-Prime or Visual Basic 6.0). During this exposure test, a heart rate recording will be made using a BIOPAC MP160 recording system.
Study NCT05328297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55308942
Description: JNJ-55308942 capsules will be administered orally.
Study NCT05328297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered orally.
Study NCT01338844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol
Study NCT01338844 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-chito-Inositol
Study NCT06244212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration of applying triamcinolone cream
Description: Live demonstration of applying 1 fingertip unit of triamcinolone cream
Study NCT06244212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile App Use
Description: Additional mobile application that provides amount dispensed and adherence data.
Study NCT06244212 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Written/verbal instructions only
Study NCT04308278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2LEBV® / 2LXFS®
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT04308278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.
Study NCT06648356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Neuromuscular electrical stimulation (NMES) is applied during an isometric contraction. The NMES uses a symmetrical biphasic rectangular pulse (50Hz frequency and 300 µs phase width) delivered through an Enraf Nonius TensMed S82 electrostimulator. Two 5x9 cm electrodes are placed on the hamstrings, and participants adjust the current to a moderate-strong, yet painless, contraction level. During the intervention, one researcher maintains the stretch position while another researcher controls the current intensity and monitors the timing of both stretching and contractions.
Study NCT06648356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contract-Relax PNF (crPNF)
Description: The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
Study NCT06648356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Contract-Relax PNF (crPNF)
Description: The crPNF Group engages in an isolated contract-relax proprioceptive neuromuscular facilitation (crPNF) stretching protocol. Participants are positioned in a long sitting posture with maximum knee extension until they feel a moderate-strong stretch sensation, without pain. Each stretch lasts for 20 seconds, followed by a 5-second maximal voluntary isometric contraction of the hamstrings. Participants complete three cycles of stretch and contraction. One researcher maintains the stretch position while a second researcher controls the timing of the stretching and contractions.
Study NCT05423197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-panitumumab IV
Description: Subjects will be given a bolus of 1.0 mCi (range 0.8 - 1.2 mCi) of 89Zr-panitumumab before undergoing further standard of care diagnostic evaluation of the lesions
Study NCT05423197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Panitumumab 30mg will be given orally
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacemaker Interrogation and Electrocardiogram (ECG):
Description: Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pacemaker Interrogation and Electrocardiogram (ECG):
Description: Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pacemaker Interrogation and Electrocardiogram (ECG):
Description: Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR
Description: Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR
Description: Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR
Description: Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous pacemaker telemetry (CPT)
Description: CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous pacemaker telemetry (CPT)
Description: CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.
Study NCT06601322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous pacemaker telemetry (CPT)
Description: CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.
Study NCT06662526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trace lithium dose plus treatment as usual
Description: Subjects assigned to the active arm will receive 50 mg of lithium per day, for five years
Study NCT06662526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill plus treatment as usual
Description: Patients will receive a placebo pill plus treatment as usual by their clinical providers
Study NCT06664697 — intervention group
Intervention type: DEVICE
Intervention: Cochlear Implantation with Robotic-Assisted Insertion System
Description: The purpose of the study is to collect additional safety data in retrospective and prospective subjects who receive a cochlear implant using the iotaSOFT Insertion System.
Study NCT06666140 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonic elastography
Description: The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive.
Study NCT06666140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonic elastography
Description: The measurement of diaphragmatic stiffness by shear waves is performed with a high-frequency linear ultrasound probe, intercostally, during apneas lasting a few seconds.~After quantitative diaphragm thickness measurements, the ultrasound probe positioning is unchanged and regions of interest are placed in the patient's diaphragm thickness as well as in the adjacent liver or spleen (baseline). A stiffness result is obtained in kPa.~The elastography measurement extends the duration of the ultrasound scheduled as part of patient care by only 10 minutes.~The examination is painless and non-invasive.
Study NCT06665048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl
Description: Administer oxycodone hydrochloride (0.1 mg/kg) intravenously half an hour before surgery.
Study NCT05490641 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glucose-based biofeedback
Description: Participants will wear a Fitbit activity tracker and receive personalized text messages over a 12-week period. During the first 4 weeks of the study period, participants will also wear a continuous glucose monitor to check their glucose levels in real-time and receive text messages based on their activity and glucose data.
Study NCT05490641 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard feedback
Description: Participants will wear a Fitbit activity tracker and receive non-personalized text messages over a 12-week period.